The U.S. Department of Health and Human Services last week clarified when hospitals are allowed to buy socalled orphan drugs at sharply discounted prices, but it left open questions for drug manufacturers about the risk of being prosecuted for off-label promotion of them.
The drugs, which are for rare diseases and named after the small “orphan” populations of fewer than 200,000 people they’re designed to treat, are among the most expensive on the market.
Originally published in Thomson Reuters on 7/31/13.
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Topics: Below-Cost Pricing, Healthcare, HHS, Hospitals, HRSA, Off-Label Promotion, Off-Label Use, Orphan Drugs, Pharmaceutical, Prescription Drugs
Published In: Health Updates, Insurance Updates, Science, Computers & Technology Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Mintz Levin - Health Law & Policy Matters | Attorney Advertising